Algernon Pharmaceuticals Inc.

CNSX:AGN Stock Report

Market Cap: CA$1.4m

Algernon Pharmaceuticals Management

Management criteria checks 3/4

Algernon Pharmaceuticals' CEO is Chris Moreau, appointed in Mar 2018, has a tenure of 6.83 years. total yearly compensation is CA$544.30K, comprised of 40.4% salary and 59.6% bonuses, including company stock and options. directly owns 7.3% of the company’s shares, worth CA$101.14K. The average tenure of the management team and the board of directors is 3.8 years and 4.3 years respectively.

Key information

Chris Moreau

Chief executive officer

CA$544.3k

Total compensation

CEO salary percentage40.4%
CEO tenure6.8yrs
CEO ownership7.3%
Management average tenure3.8yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Moreau's remuneration changed compared to Algernon Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024n/an/a

-CA$503k

May 31 2024n/an/a

-CA$3m

Feb 29 2024n/an/a

-CA$5m

Nov 30 2023n/an/a

-CA$5m

Aug 31 2023CA$544kCA$220k

-CA$7m

May 31 2023n/an/a

-CA$6m

Feb 28 2023n/an/a

-CA$6m

Nov 30 2022n/an/a

-CA$7m

Aug 31 2022CA$576kCA$220k

-CA$6m

May 31 2022n/an/a

-CA$4m

Feb 28 2022n/an/a

-CA$5m

Nov 30 2021n/an/a

-CA$6m

Aug 31 2021CA$256kCA$220k

-CA$8m

May 31 2021n/an/a

-CA$10m

Feb 28 2021n/an/a

-CA$13m

Nov 30 2020n/an/a

-CA$12m

Aug 31 2020CA$257kCA$157k

-CA$9m

May 31 2020n/an/a

-CA$6m

Feb 29 2020n/an/a

-CA$2m

Nov 30 2019n/an/a

-CA$2m

Aug 31 2019CA$108kCA$108k

-CA$2m

May 31 2019n/an/a

-CA$2m

Feb 28 2019n/an/a

-CA$2m

Nov 30 2018n/an/a

-CA$1m

Aug 31 2018CA$108kCA$54k

-CA$938k

Compensation vs Market: Chris's total compensation ($USD376.77K) is above average for companies of similar size in the Canadian market ($USD166.13K).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Moreau (59 yo)

6.8yrs

Tenure

CA$544,302

Compensation

Mr. Christopher J. Moreau, also known as Chris, has been Chief Executive Officer and Director at Algernon Neuroscience Inc., since December 9, 2022. He has been Chief Executive Officer at Algernon Pharmace...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Moreau
CEO & Director6.8yrsCA$544.30k7.3%
CA$ 101.1k
James Kinley
Chief Financial Officer3.1yrsCA$290.10k5.02%
CA$ 69.5k
Christopher Bryan
Vice President of Research & Operations3.8yrsCA$300.10kno data

3.8yrs

Average Tenure

46yo

Average Age

Experienced Management: AGN's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Moreau
CEO & Director4.7yrsCA$544.30k7.3%
CA$ 101.1k
Harold J. Bloomfield
Independent Chairman of the Board3.3yrsCA$187.17k1.8%
CA$ 24.9k
Howard Gutman
Director2.9yrsCA$93.43k0.81%
CA$ 11.3k
Peter Dicpinigaitis
Medical Consultant of Chronic Cough Research Prgm. & Member of Medical and Scientific Advisory Board2yrsno datano data
Rajpaul Attariwala
Independent Director9.3yrsCA$81.94k0.54%
CA$ 7.5k
David Nutt
Member of Medical & Scientific Advisory Boardno datano datano data
Mark Williams
Director3.3yrsCA$86.94k0.21%
CA$ 2.9k
Martin Kolb
Member of Medical & Scientific Advisory Board5.1yrsno datano data
Jacky Smith
Member of Medical & Scientific Advisory Board4.9yrsno datano data
Mark Swaim
Member of Medical & Scientific Advisory Board4.3yrsno datano data
Rick Strassman
Member of Medical & Scientific Advisory Boardno datano datano data
Ede Frecska
Member of Medical & Scientific Advisory Boardno datano datano data

4.3yrs

Average Tenure

59yo

Average Age

Experienced Board: AGN's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 04:42
End of Day Share Price 2025/01/03 00:00
Earnings2024/08/31
Annual Earnings2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Algernon Pharmaceuticals Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andre UddinResearch Capital Corporation